FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783013874> ?p ?o ?g. }

• W2783013874 endingPage "514" @default.
• W2783013874 startingPage "505" @default.
• W2783013874 abstract "Access to trastuzumab, a valuable anti-cancer treatment, can be limited by cost. The primary aim of this study was to evaluate and compare the PK profiles of CT-P6, a biosimilar of trastuzumab, and US-licensed reference trastuzumab (Herceptin®) in healthy subjects. Secondary study aims included comparison of the safety and immunogenicity of CT-P6 and reference trastuzumab in these subjects. We performed a single-dose, randomised, double-blind, parallel group study (NCT02665637) comparing CT-P6 with reference trastuzumab (6 mg/kg, 90 min intravenous infusion) in 70 healthy adult males. Pharmacokinetics, safety and immunogenicity were evaluated up to 10 weeks post-dose. Primary endpoints were area under the serum concentration–time curve (AUC) from time 0 to infinity (AUCinf); AUC from time 0 to last quantifiable concentration (AUClast); and observed maximum serum concentration (Cmax). The pre-determined equivalence criterion was a 90% confidence interval of 80–125% for ratios of geometric least squares (LS) means. Equivalence of CT-P6 and reference trastuzumab was demonstrated. Ratios (CT-P6/reference trastuzumab) of geometric LS means (90% confidence interval) were: AUCinf 99.05 (93.00, 105.51); AUClast 99.30 (92.85, 106.20); Cmax 96.58 (90.93, 102.59). Safety profiles were similar; treatment-emergent adverse events occurred in ten subjects (28.6%) in the CT-P6 group and 11 (31.4%) in the reference trastuzumab group. No serious adverse events or deaths occurred. No subjects tested positive for anti-drug antibodies. These data add to the totality of evidence required to demonstrate biosimilarity. A phase III study of CT-P6—in which equivalent neoadjuvant efficacy to reference trastuzumab has been demonstrated—is ongoing." @default.
• W2783013874 created "2018-01-26" @default.
• W2783013874 creator A5022691552 @default.
• W2783013874 creator A5046740580 @default.
• W2783013874 creator A5066408904 @default.
• W2783013874 creator A5076575654 @default.
• W2783013874 creator A5079409805 @default.
• W2783013874 creator A5087724207 @default.
• W2783013874 date "2018-01-12" @default.
• W2783013874 modified "2023-10-12" @default.
• W2783013874 title "A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab" @default.
• W2783013874 cites W1147832057 @default.
• W2783013874 cites W155933052 @default.
• W2783013874 cites W1964321121 @default.
• W2783013874 cites W1985202864 @default.
• W2783013874 cites W1987326983 @default.
• W2783013874 cites W2003403455 @default.
• W2783013874 cites W2006174096 @default.
• W2783013874 cites W2006502925 @default.
• W2783013874 cites W2016637221 @default.
• W2783013874 cites W2024670380 @default.
• W2783013874 cites W2053883514 @default.
• W2783013874 cites W2095156669 @default.
• W2783013874 cites W2095865154 @default.
• W2783013874 cites W2096884232 @default.
• W2783013874 cites W2098775844 @default.
• W2783013874 cites W2100439220 @default.
• W2783013874 cites W2117984780 @default.
• W2783013874 cites W2125620887 @default.
• W2783013874 cites W2127248987 @default.
• W2783013874 cites W2146269515 @default.
• W2783013874 cites W2146384083 @default.
• W2783013874 cites W2146406055 @default.
• W2783013874 cites W2149773268 @default.
• W2783013874 cites W2163750567 @default.
• W2783013874 cites W2169560977 @default.
• W2783013874 cites W2318605753 @default.
• W2783013874 cites W2402233591 @default.
• W2783013874 cites W2530856438 @default.
• W2783013874 cites W2546196047 @default.
• W2783013874 cites W2556376431 @default.
• W2783013874 cites W2567249615 @default.
• W2783013874 cites W2574068890 @default.
• W2783013874 cites W2620735862 @default.
• W2783013874 cites W2757511999 @default.
• W2783013874 cites W4211007657 @default.
• W2783013874 cites W4239989216 @default.
• W2783013874 cites W4252714226 @default.
• W2783013874 doi "https://doi.org/10.1007/s00280-017-3510-7" @default.
• W2783013874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29330636" @default.
• W2783013874 hasPublicationYear "2018" @default.
• W2783013874 type Work @default.
• W2783013874 sameAs 2783013874 @default.
• W2783013874 citedByCount "31" @default.
• W2783013874 countsByYear W27830138742018 @default.
• W2783013874 countsByYear W27830138742019 @default.
• W2783013874 countsByYear W27830138742020 @default.
• W2783013874 countsByYear W27830138742021 @default.
• W2783013874 countsByYear W27830138742022 @default.
• W2783013874 countsByYear W27830138742023 @default.
• W2783013874 crossrefType "journal-article" @default.
• W2783013874 hasAuthorship W2783013874A5022691552 @default.
• W2783013874 hasAuthorship W2783013874A5046740580 @default.
• W2783013874 hasAuthorship W2783013874A5066408904 @default.
• W2783013874 hasAuthorship W2783013874A5076575654 @default.
• W2783013874 hasAuthorship W2783013874A5079409805 @default.
• W2783013874 hasAuthorship W2783013874A5087724207 @default.
• W2783013874 hasBestOaLocation W27830138741 @default.
• W2783013874 hasConcept C112705442 @default.
• W2783013874 hasConcept C121608353 @default.
• W2783013874 hasConcept C126322002 @default.
• W2783013874 hasConcept C143998085 @default.
• W2783013874 hasConcept C159654299 @default.
• W2783013874 hasConcept C197934379 @default.
• W2783013874 hasConcept C203014093 @default.
• W2783013874 hasConcept C22979827 @default.
• W2783013874 hasConcept C2779786085 @default.
• W2783013874 hasConcept C2780868878 @default.
• W2783013874 hasConcept C44249647 @default.
• W2783013874 hasConcept C530470458 @default.
• W2783013874 hasConcept C59491497 @default.
• W2783013874 hasConcept C71924100 @default.
• W2783013874 hasConcept C98274493 @default.
• W2783013874 hasConceptScore W2783013874C112705442 @default.
• W2783013874 hasConceptScore W2783013874C121608353 @default.
• W2783013874 hasConceptScore W2783013874C126322002 @default.
• W2783013874 hasConceptScore W2783013874C143998085 @default.
• W2783013874 hasConceptScore W2783013874C159654299 @default.
• W2783013874 hasConceptScore W2783013874C197934379 @default.
• W2783013874 hasConceptScore W2783013874C203014093 @default.
• W2783013874 hasConceptScore W2783013874C22979827 @default.
• W2783013874 hasConceptScore W2783013874C2779786085 @default.
• W2783013874 hasConceptScore W2783013874C2780868878 @default.
• W2783013874 hasConceptScore W2783013874C44249647 @default.
• W2783013874 hasConceptScore W2783013874C530470458 @default.
• W2783013874 hasConceptScore W2783013874C59491497 @default.
• W2783013874 hasConceptScore W2783013874C71924100 @default.
• W2783013874 hasConceptScore W2783013874C98274493 @default.

• next